Literature DB >> 21220601

High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?

Paul A Meyers, Carlos Flombaum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220601     DOI: 10.1200/JCO.2010.32.8245

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Authors:  Jeffrey R Scott; Yinmei Zhou; Cheng Cheng; Deborah A Ward; Hope D Swanson; Alejandro R Molinelli; Clinton F Stewart; Fariba Navid; Sima Jeha; Mary V Relling; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

2.  Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.

Authors:  Brigitte C Widemann
Journal:  Pediatr Blood Cancer       Date:  2015-10-21       Impact factor: 3.167

Review 3.  Preventing and Managing Toxicities of High-Dose Methotrexate.

Authors:  Scott C Howard; John McCormick; Ching-Hon Pui; Randall K Buddington; R Donald Harvey
Journal:  Oncologist       Date:  2016-08-05

4.  Methotrexate-Induced Toxic Epidermal Necrolysis: A Rare Case Report and Review of Literature.

Authors:  Pritam Kataria; Pradip Kendre; Apurva Patel; Nahush Tahiliani; Sushant Ikhar
Journal:  Indian J Crit Care Med       Date:  2018-10

5.  Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study.

Authors:  Berna Demiralp; Lane Koenig; Jaya Kala; Chaoling Feng; Elizabeth G Hamlett; Marie Steele-Adjognon; Suzanne Ward
Journal:  Clinicoecon Outcomes Res       Date:  2019-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.